India's bio-economy faces existential threats from US tariffs and Chinese breakthroughs, demanding urgent governance reform. To dominate the value chain and remain the "pharmacy of the world," current colonial and control-minded administrative structures must be overhauled. These outdated policies stifle innovation, delaying vital clinical trials. Consolidating machinery to promote growth, attract capital, upgrade quality standards, and employ fiscal levers is critical. Without structural changes, India risks economic coercion, missing a projected $2.6 trillion opportunity and global biotech power status. A proactive national strategy is vital.